Summary:
We are currently recruiting for a facet joint osteoarthritis study testing investigational drug XT-150. This treatment is for adult participants experiencing low back pain due to inflammation caused by the facet joint osteoarthritis (FJOA) who are eligible for intra-articular glucocorticoid steroid injection, or radiofrequency ablation of medial branches of the primary dorsal ramus. The possible benefits of this clinical study include longer-term relief in individuals experiencing pain from facet joint osteoarthritis.
Subjects will be evaluated at baseline and followed through 9 months to establish safety and efficacy of the treatment. The study drug will be administered as bilateral injections to the facet joints at the determined level, with a repeat injection at the 90 day mark.
Criteria:- Be age 18 to 90 years old
- Have severe facet arthropathy
- Low back pain worsened by activity or motion of region
- No prior history of lumbar fusion surgery
- No radiofrequency ablation within the last 12 months
Qualified Participants May Receive:
This study involves a total of 13 visits at our site including screening, injection day, Day 7, 14, 30, 60, 90, 120, 150, 180, 210, 240, and 270 follow-up. There is no cost to the participant for the investigational product, office visits, examinations, and laboratory tests that are required by the study. Compensation will be provided to subjects.